Matinas BioPharma Holdings, Inc. Terminates At-The-Market Sales Agreement with BTIG
Key Developments
- Termination of Sales Agreement: On July 23, 2026, Matinas BioPharma Holdings, Inc. (“Matinas” or “the Company”) received notice from BTIG that the At-The-Market (“ATM”) Sales Agreement, originally entered into on July 2, 2020, has been terminated effective immediately.
- Details of the Sales Agreement: The agreement allowed Matinas to offer and sell shares of its common stock (par value \$0.0001 per share), with a total potential value of up to \$50,000,000, through “at-the-market” offerings as defined under Rule 415 of the Securities Act of 1933, as amended.
- No Termination Penalties: The Company is not subject to any termination penalties or additional expenses as a result of the agreement’s termination.
- Regulatory Filing: The details of this termination were disclosed in a Form 8-K filed with the Securities and Exchange Commission, fulfilling the Company’s legal disclosure obligations.
Implications for Shareholders
- Potential Impact on Capital Raising: The ATM program had been a flexible tool for Matinas to raise capital by selling shares directly into the market at prevailing prices. With the termination of this agreement, the Company has lost a key mechanism for immediate, opportunistic fundraising.
- Share Value Considerations: The discontinuation of the ATM facility may signal that Matinas is either confident in its current liquidity position or may be seeking alternative financing arrangements. Investors should consider whether this impacts the Company’s ability to fund ongoing operations, strategic initiatives, or R&D activities, especially given the biotech sector’s typically high cash burn rates.
- No Immediate Financial Obligation: The absence of penalties or extra fees from the termination is a positive, as it does not create a new financial burden for the Company.
- Regulatory and Exchange Details: Matinas’s common stock remains listed on the NYSE American under the ticker symbol “MTNB”.
- Emerging Growth Company Status: The Company is not classified as an “emerging growth company” under the SEC’s definitions, which may have implications for its regulatory reporting and compliance obligations.
What Investors Should Watch
- Future Capital Raising: Investors should monitor for announcements regarding alternative fundraising strategies, such as private placements, debt financing, or new equity offerings.
- Business and Cash Position: The loss of the ATM program could increase scrutiny of the Company’s balance sheet and cash runway, particularly if Matinas is in a phase of heavy investment or clinical development.
- Strategic Shifts: The termination could precede a strategic transaction or shift in business model, although no such plans have been disclosed as of this filing.
Conclusion
The immediate termination of the \$50 million At-The-Market Sales Agreement with BTIG removes a flexible capital-raising option for Matinas BioPharma. While the Company faces no termination penalties, investors should closely watch for further disclosures regarding the Company’s financial strategy and capital needs. The news may have implications for the Company’s share price, depending on investor perceptions of Matinas’s future funding capabilities and strategic direction.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with a qualified financial advisor before making investment decisions. The information above is based on publicly available filings as of July 23, 2026.
